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Abstract
Background: Symptoms arising from vestibular system dysfunction are observed in 49–59% of people with
Multiple Sclerosis (MS). Symptoms may include vertigo, dizziness and/or imbalance. These impact on functional
ability, contribute to falls and significant health and social care costs. In people with MS, vestibular dysfunction can
be due to peripheral pathology that may include Benign Paroxysmal Positional Vertigo (BPPV), as well as central or
combined pathology. Vestibular symptoms may be treated with vestibular rehabilitation (VR), and with
repositioning manoeuvres in the case of BPPV. However, there is a paucity of evidence about the rate and degree
of symptom recovery with VR for people with MS and vestibulopathy. In addition, given the multiplicity of
symptoms and underpinning vestibular pathologies often seen in people with MS, a customised VR approach may
be more clinically appropriate and cost effective than generic booklet-based approaches. Likewise, BPPV should be
identified and treated appropriately.
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Methods/ design: People with MS and symptoms of vertigo, dizziness and/or imbalance will be screened for
central and/or peripheral vestibulopathy and/or BPPV. Following consent, people with BPPV will be treated with re-
positioning manoeuvres over 1–3 sessions and followed up at 6 and 12 months to assess for any re-occurrence of
BPPV. People with central and/or peripheral vestibulopathy will be entered into a randomised controlled trial (RCT).
Trial participants will be randomly allocated (1:1) to either a 12-week generic booklet-based home programme with
telephone support or a 12-week VR programme consisting of customised treatment including 12 face-to-face
sessions and a home exercise programme. Customised or booklet-based interventions will start 2 weeks after
randomisation and all trial participants will be followed up 14 and 26 weeks from randomisation. The primary
clinical outcome is the Dizziness Handicap Inventory at 26 weeks and the primary economic endpoint is quality-
adjusted life-years. A range of secondary outcomes associated with vestibular function will be used.
Discussion: If customised VR is demonstrated to be clinically and cost-effective compared to generic booklet-based
VR this will inform practice guidelines and the development of training packages for therapists in the diagnosis and
treatment of vestibulopathy in people with MS.
Trial registration: ISRCTN Number: 27374299
Date of Registration 24/09/2018
Protocol Version 15 25/09/2019
Keywords: Multiple sclerosis, Vestibular, Vertigo, Balance, Benign paroxysmal positional vertigo, Vestibulopathy,
Rehabilitation, Randomised controlled trial
Background
Vestibulopathy causes perceptual deficits (e.g. vertigo or
dizziness, poor perception of vertical) and abnormalities
in the control of eye movements and balance. Symptoms
arising from vestibulopathy are common in people with
Multiple Sclerosis (MS). Dizziness affects 49–59% of
people with MS [1], with true rotational vertigo, an indi-
cator of vestibular-induced dizziness, affecting approxi-
mately 20% [2]. In people with MS who report dizziness,
38.5% rate it as having a moderate or severe impact [1].
A greater severity of dizziness is associated with a lower
quality of life [1]. Abnormalities in vestibular evoked
ocular and spinal reflexes, that are important for the
stabilisation of gaze and balance, are seen in 40–86% of
people with MS. [3–9] Vestibulopathy, combined with
clinical signs of lower limb weakness, sensory loss, ataxia
and spasticity, may result in balance and mobility im-
pairment [10–13]. This can result in falls and injuries,
restriction in outdoor mobility and a subsequent impact
on social participation and quality of life for individuals
[14–19]. The balance dysfunction and reduced mobility
seen in people with MS are further associated with sig-
nificant health and social care costs [18, 20].
The vestibular system consists of a peripheral pathway
(the inner ear and vestibular nerve) and central pathways
in the brain (e.g. the vestibular nuclei and cerebellum)
that process vestibular signals [21]. Although MS affects
the central nervous system (CNS), people with MS can
present with peripheral symptoms if the lesion affects
the vestibular nerve in isolation as it enters the CNS
[22]. Further, Benign Paroxysmal Positional Vertigo
(BPPV), a condition affecting the inner ear, has been
reported in around 50% of people with MS who attend
specialised neuro-otology clinics [22, 23]. The cause and
management of BPPV is different to that of peripheral
or central vestibulopathy, hence it is important to iden-
tify this condition in order to manage it appropriately.
In BPPV, otoconia crystals become dislodged from the
otolith macula and become trapped within the semicir-
cular canals; usually the posterior canal is affected. BPPV
can be diagnosed using the Dix-Hallpike manoeuvre that
moves the head in the plane of the posterior canal.
When otoconia are present in the canal this leads to de-
viation or deflection of the cuplua and reflexive, charac-
teristic eye movements. BPPV is treatable with bedside
physical manoeuvres such as Epley or Semont, which
aim to move these crystals back into the otoliths. A
Cochrane systematic review highlights that compared to
no intervention these manoeuvres, in otherwise healthy
participants, are very effective at reducing symptoms of
vertigo (odds ratio 4.42[2.62–7.44]) and producing a
negative Dix –Hallpike test (odds ratio 9.62 [6–15.42])
[24]. However, symptoms can re-occur in 36% of cases
over 48 months [24] and re-occurrence rates are greater
in people with migraine or head injury [25, 26]. It is un-
clear whether repositioning manoeuvres have the same
short and long term effectiveness in people with MS
compared to the general, otherwise healthy, population.
Currently, testing and repositioning manoeuvres for
BPPV in people with MS are not routinely performed.
Therefore, nested within this study, we plan to under-
take a observational study to determine the success rate
of repositioning manoeuvres and re-occurrence rate of
symptoms in pwMS who are assessed as having BPPV.
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Prognosis for recovery with rehabilitation for vestibu-
lopathy in the general population varies with aetiology,
being greater for peripheral disorders compared to cen-
tral disorders [27]. Symptom recovery involves adaptive
changes in the brain, termed vestibular compensation
[27]. Recovery can be affected by other factors such as
additional sensory dysfunction (somatosensory and/or
visual), restricted head motion, lack of mobility, long
term use of anti-vertiginous drugs, fatigue and psycho-
logical problems such as depression, phobias and anxiety
[28]. Therefore, identifying factors affecting prognosis
may, in future, aid screening and management of people
with MS and vestibulopathy. Clinical tests such as HINT
S (head impulse, nystagmus and skew deviation) can
differentiate peripheral and central vestibulopathy [29].
If these tests can be shown to be as sensitive and specific
as laboratory-based measures (e.g. using a rotary chair
and videonystamography) in people with MS, the use of
such tests would aid in the clinical diagnosis and plan-
ning of treatment.
Vestibular rehabilitation (VR) is the standard of care
for people with vestibulopathy. VR involves progressive
exercises including eye, head, and body movements in
sitting, standing, and walking. In otherwise healthy
people with a peripheral vestibular disorder, a Cochrane
systematic review concluded that there is moderate to
strong evidence to support VR as a safe, effective man-
agement option, with clinically and statistically signifi-
cant improvements noted for perceptual, oculomotor
and balance symptoms [30]. In contrast, the effectiveness
of rehabilitation for dizziness where solely central vestibu-
lar pathways have been damaged has only been explored
in studies with small numbers of patients with varying
pathology [31–37]. These studies suggest that improve-
ments in symptoms and balance for people with a central
vestibular disorder can be achieved, although not always
to the same extent as in people with peripheral vestibular
disorders. However, these studies did not include people
with MS. Rather, the studies involve people with heredi-
tary conditions, head injury, or stroke. The studies were
retrospective or isolated case reports and did not have
concurrent control groups. Furthermore, the studies fre-
quently did not use validated outcome measures.
Two recent systematic reviews have investigated the
effectiveness of VR in people with MS. [38, 39] Synnott
and Baker reviewed the effect of VR reported in seven
RCTs [40–46] representing a total of 323 people, aged
20–63 with a range of MS phenotypes [38]. The authors
reported a wide variety of VR treatment protocols with
respect to content and intensity. Frequency of supervised
VR sessions varied from twice daily to once a week, with
four studies incorporating a home exercise programme
between 1 and 7 days a week. Similarly, the duration of
interventions were variable ranging from 4 to 14 weeks.
Four studies compared VR with usual care, two with
neurological rehabilitation, and one compared VR custo-
mised to the participants’ symptoms with a standard for-
mat VR. All included studies investigated the effectiveness
of VR on a balance related outcome measure. In addition,
three studies investigated the effectiveness of VR on dizzi-
ness, and three on fatigue. These authors concluded that
VR is a safe and effective intervention offering short term
improvements in balance in people with MS. However,
they also noted that evidence for optimal VR prescription
and long-term effects of VR is limited. The second review
[39] included seven articles [40, 41, 44–48], reporting on
six RCTs of VR in people with MS (n = 321, mean age
43.6 years). Two of the articles were different to those in-
cluded in the previous review [47, 48]. The authors con-
cluded that VR is more effective than no intervention for
gaining improvements in balance, dizziness and fatigue in
people with MS. However, they reported a non-statistically
significant difference between groups when VR was com-
pared with other exercise interventions, suggesting that
there is insufficient evidence to conclude that VR is more
effective than other exercise-based interventions.
To date, only one pilot study has evaluated a customised
approach to VR compared to generic VR in people with
MS [42], and the cost-effectiveness of such interventions
has not been explored in people with MS. Customised VR
programmes include a comprehensive assessment of
balance and oculomotor control and the provision of
exercises specifically selected to treat each individual’s
identified impairment or functional limitations and ad-
dress their individual goals. In otherwise healthy people
with peripheral vestibulopathy a customised, individua-
lised VR programme that targets patient-specific problems
has been demonstrated to be more effective than a generic
VR exercise programme [49–51].
Many people with vestibular disorders also report
symptoms of visually induced dizziness, which refers to
symptoms specifically triggered or exacerbated by com-
plex, unusual or moving visual stimuli, including crowds,
scrolling on the computer screen and watching moving
traffic [52]. It is a frequent and at times debilitating
symptom associated with high levels of disability, pro-
longed illness and poorer clinical outcome in people with
vestibulopathy [53]. Visually induced dizziness responds
well to customized VR programmes that incorporate
structured exposure to visual motion stimuli [54].
Despite this evidence, standard care of isolated vestibular
symptoms in otherwise healthy participants in many UK
centres continues to include, at best, only standardised,
generic exercises, delivered using a booklet after an initial
one-to-one session or group class. Given the complexity of
symptom presentation in people with MS it may be that
customised exercises are more effective and cost effective
than home based generic exercises delivered via a booklet.
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Aims
The primary aim of this research is to compare the clinical
and cost effectiveness of a 12-week VR programme, con-
sisting of 12 face-to-face sessions and a customised home-
based programme plus usual care, to a 12-week generic
booklet-based home programme with telephone support
plus usual care, in ambulant people with MS with associ-
ated peripheral and/ or central vestibulopathy.
The secondary aims are to investigate factors affecting
recovery from vestibulopathy with VR, and to explore
the sensitivity and specificity of clinical bedside tests in
diagnosis of central and peripheral vestibulopathy and in
predicting treatment outcome. The nested observational
study will determine the success and reoccurrence rate
of symptoms with repositioning manoeuvres in pwMS
who have clinically defined BPPV.
Objectives
1. Assess the clinical effectiveness of a customised VR
programme compared to a generic booklet-based
VR programme on subjective reports of the
perceived impact of vertigo or dizziness symptoms
as measured by the Dizziness Handicap Inventory
(primary outcome).
2. Assess the clinical effectiveness of a customised VR
programme compared to a generic booklet-based VR
programme on self-reported balance confidence and
walking ability and objective measures of standing
balance, functional gait and visual dependency for
perceptual orientation responses (secondary
outcomes).
3. Assess the adherence to a customised VR
programme compared to a generic booklet-based
VR programme.
4. Establish the intervention costs of the customised
and generic booklet-based VR and conduct a full
cost-effectiveness analysis.
5. Explore the impact of the underlying vestibular
pathology (peripheral, central, or combined) and
associated symptoms (weakness, distal
somatosensory loss, visual dependency,
psychological state) with treatment outcome.
6. Explore the sensitivity and specificity of bedside tests
for the diagnosis of central and peripheral
vestibulopathy and in predicting treatment outcome.
7. To determine the success and reoccurrence rate of
symptoms with repositioning manoeuvres in pwMS
who have clinically defined BPPV.
Methods
Randomised controlled trial design
The study is a multi-centre parallel group, superiority
randomised controlled trial (RCT) with blinded outcome
assessment. Ambulant individuals with MS and periph-
eral or central vestibulopathy will be randomised in a 1:1
ratio to either a customised 12-week VR programme
consisting of 12 face-to-face sessions and a customised
home-based programme plus usual care (“Intervention
group”), or a generic home-based exercise programme
delivered using a booklet and telephone support plus
usual care (“Control group”).
Observational study design
A longitudinal cohort observational study will determine
the success and re-occurrence rate of symptoms with
repositioning manoeuvres in pwMS who have clinically
defined BPPV.
Trial settings
The sites involved are based in two geographical regions
of the UK: South West England (Devon and Cornwall)
and London.
Participants
Eligibility criteria
Inclusion criteria
The study population will comprise individuals diag-
nosed with MS (relapsing remitting, primary or second-
ary progressive) according to McDonald’s revised criteria
[55, 56]. These participants will:
 be aged > 18 years
 be willing and able to consent
 score 1–6 on Patient Determined Disease Steps,
equivalent to Expanded Disability Status Scale
(EDSS) 2–6.5
 report one of the following at least 4 times/month:
◦ feeling that things are spinning or moving
around
◦ a feeling of being light-headed, “swimmy” or
giddy
◦ feeling unsteady and about to lose balance
 willing and able to travel to, and participate in, the
12 face to face sessions should they be allocated to
the intervention group and to commit to
undertaking their individualised home-based
programme
 willing and able to travel to local assessment centres
for screening and baseline tests and blinded
outcomes assessment.
 People eligible for the nested observational study
will in addition have a a positive diagnosis of BPPV
determined by tests for posterior (Dix- Hallpike) and
horizontal canal BPPV (horizontal head rotation in
supine with the head in 30o flexion) [57].
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Exclusion criteria
People will be excluded if they:
 have neurological conditions other than MS as
determined from clinical notes
 have relapsed or received steroid treatment within
the last month
 currently or recently (within past 6 months)
participated in a VR programme
 have an orthopaedic deficit which may impact on
postural and gait testing or significant pain or
weakness (> 4/10 on a numerical rating scale)
associated with osteo- or rheumatoid arthritis
 have dizziness solely explained by other causes
(e.g. postural hypotension)
 have a headache or migraine associated with a
subjective report of one of the following at least 4
times/month:
◦ nausea (feeling sick), stomach churning
◦ vomiting
 have been taking vestibular sedatives specifically for
the treatment of vertigo for more than 4 weeks. If
people have been regularly taking vestibular
sedatives (> 4 weeks) and, with approval of their
neurologist and/or GP, they stop the medication
then they will be eligible to take part in the study
after a 6 week wash out period following re-
screening.
Identification and recruitment of participants will be
via a number of routes, including screening regional MS
databases, healthcare professionals, and advertising via
local MS support groups and newsletters.
Sample size
Randomised control trial
The primary outcome measure is the Dizziness Handi-
cap Inventory (DHI) [58], assessed at the primary end-
point of 26 weeks (±2 weeks) post randomisation. The
sample size calculation is based on data from a MS ves-
tibular waitlist control study [40], where the mean
between-group differences in the change in DHI were
16.5 units and 18.1 units for the intervention vs exercise
group and intervention vs wait-listed group, respectively;
equivalent to standardised effect sizes (for change in
DHI) of 1.03 and 1.12. The study reported a standard
deviation of the difference between DHI at baseline and
end of intervention of 20.7 for the intervention group
and 9.6 for the wait-listed control group. Pooling these
values gives an estimated standard deviation of the
changes in DHI of 15.9, which was used in the sample
size calculation for this trial.
Primary outcome data (change in DHI) based on 25
participants per group would enable a standardised
effect size of ~ 0.94 to be detected with 90% power, or
0.81 with 80% power, at the two-sided 5% significance
level. To account for participant drop out, the aim is to
recruit at least 70 participants (35 per allocated group).
Observational study
Based on being able to recruit 140 participants to the
main project (given the resources available), and assum-
ing approximately 50% of pwMS present with BPPV [22,
23], it is anticipated that approximately 70 people will be
enrolled in the observational study. The primary aim of
the observational study is to estimate the recurrence rate
of BPPV. Based on data from Hilton et al. 2014 [24], the
expected precision of the estimate of recurrence, based
on a range of sample sizes and recurrence rates, and
after allowing for 10% loss to follow-up by the end of
the one-year period, are provided in Table 1.
Screening
Figure 1 indicates the flow of participants. Initially,
people will be screened by telephone for subjective
symptoms of vertigo and dizziness and poor balance,
based on questions 4, 6 and 10 of the Vertigo Symptom
Scale (short version [59]).
If deemed eligible following telephone screening, they
will attend an initial first face-to-face visit.
Screening for BPPV
Participants will be screened for posterior canal BPPV
using the Dix-Hallpike manoeuvre and horizontal canal
BPPV using a roll test. Those with a positive BPPV test
Table 1 Expected precision of the estimate of recurrence,
based on a range of sample sizes and recurrence rates, after
allowing for 10% loss to follow-up by the end of the one- year
period. These are based on exact confidence intervals for the
proportion of recurrences, using the Clopper-Pearson method
Sample size Estimated margin of error (%)
Total number
of participants
recruited to
trial 2
Total number
of trial 2
participants
followed-up
Recurrence rate (%)
10 15 20 25 30 35
30 27 13.4 14.8 15.9 17.6 18.2 18.7
35 32 11.5 13.8 14.6 16.0 16.5 17.3
40 36 11.5 12.4 13.9 15.0 15.9 16.5
45 41 10.2 11.8 13.0 14.0 14.7 15.3
50 45 10.2 11.5 12.5 13.3 14.2 14.7
55 50 9.2 10.5 11.8 12.6 13.4 13.8
60 54 8.6 10.3 11.4 12.3 12.8 13.3
65 59 8.5 9.9 10.9 11.7 12.3 12.7
70 63 8.0 9.3 10.6 11.3 11.9 12.3
75 68 7.9 9.1 10.2 10.8 11.4 11.9
80 72 7.5 8.9 9.7 10.5 11.1 11.5
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will be excluded from the RCT and treated with the
appropriate re-positioning manoeuvre. After providing
informed consent, these individuals will then be entered
into an observational study and followed up at 6 and 12
months to assess for any re-occurrence of BPPV, as de-
tailed in the section “Nested observational study”.
Screening tests for peripheral and central vestibulopathy
People who are negative for BPPV will then be screened
for signs of peripheral and central vestibulopathy using a
neuro-otological assessment. This will be conducted by a
Band 7 Audiologist with support of the Research Therapist
at the Royal Ear, Nose and Throat Hospital London and
the trained Research Therapist at the Plymouth University
site with support from a consultant clinical scientist. The
assessment will include a videonystagmography (VNG)
recording of:
 gaze (+/− 30°) with/without optic fixation,
 saccades (at 0° and +/− 30°, assessing for velocity,
accuracy, main sequence and disconjugacy
(internuclear ophthalmoplegia INO),
 smooth pursuit at 0.2, 0.3 and 0.4 Hz (with peak
velocities of 38, 56.5, and 76°/s, respectively,
assessing for saccadic intrusions),
 optokinetic responses to a full-field striped display
moving at 40°/s (assessing for symmetry),
 Vestibulo-ocular reflex (VOR): Sinusoidal rotation at
0.2 Hz with/without visual fixation and impulsive
rotation (until nystagmus subsides, approximately
Fig. 1 Flow diagram of patient pathway
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45 s - maximum 100 s later) with an initial 140°/s
acceleration/deceleration and a 60°/s fixed-chair velocity
 VOR suppression. VOR suppression is considered
normal when no measurable nystagmus was
recorded during visual fixation.
Based on the pattern of responses the participants will
be classified as having:
 No vestibular pathology and will not be included in
the study
 Peripheral unilateral vestibular impairment
 Peripheral bilateral vestibular hypofunction
 Central vestibular impairment
 Combined central and peripheral vestibulopathy.
Randomised control trial
Randomisation
Participants identified to have a peripheral or central ves-
tibular impairment will be invited to participate in the
RCT. An online web-based system (www.redcapcloud.
com) provided by the UKCRC-registered Peninsula Clin-
ical Trials Unit (PenCTU) will be employed for random-
isation. A minimisation procedure with a random element
will be used to allocate participants to either the generic
booklet-based programme (control group) or the custo-
mised VR Programme (intervention group). The following
factors will be used in the minimisation procedure:
 Diagnosis: Peripheral (unilateral or bilateral) vs
central/ combined vestibulopathy
 Severity of dizziness: DHI ≥59 or DHI < 59. People
with MS with a score of over 59 have higher rates of
falling [60]
 Fampridine: Prescribed or not prescribed
 Region: South West England or London
Blinding
Participants will be not be blinded to group allocation as
the intervention arm involves weekly one-to-one ses-
sions with the Treating Therapist at the respective study
site. Following randomisation via the online web-based
system (www.redcapcloud.com) the treating therapist is
informed via e mail of the group allocation. The Treat-
ing Therapists and health care providers are also unable
to be blinded due to the nature of the programmes.
However, the Research Therapists undertaking the out-
come assessments will be blinded to the participants’
allocated group.
The initial baseline assessment will be undertaken
prior to randomisation ensuring these assessments are
blinded. Every effort will be made throughout to ensure
that subsequent assessments are blinded, for example by
reminding participants at the start of the visit not to
discuss their exercises or physiotherapy with the blinded
Research Therapist. At each assessment time point, the
blinded Research Therapists will be asked to record on
the case report form (CRF) whether or not they have
been un-blinded to group allocation, and if so the reason
for this. In cases where Research Therapists were not
un-blinded they will be asked to guess the group alloca-
tion for each participant.
Interventions: randomised controlled trial
Generic booklet-based VR (control group)
The generic VR exercise group will undertake a one-
hour individualised physiotherapy session during which
they will receive the validated self-management booklet
‘Balance Rehabilitation’ [61]. The booklet explains how
VR exercises help to improve vestibular symptoms and
provides instructions on how to conduct the exercises.
The Treating Therapist will provide further verbal in-
structions on how to use the booklet. Participants will
be asked to practise the exercises unsupervised at home
for 10 min, twice a day for 12 weeks and to fill out a
daily diary sheet indicating treatment duration and con-
tent. They will receive telephone support from the
Treating Therapist in the form of two 15 min phone
calls, one in week 1 and one in week 4. These contacts
will be guided by an interview schedule and focus on ad-
herence, barriers to adherence and discussion of any
concerns and queries regarding the exercise programme.
Customised VR (intervention group)
The customized vestibular rehabilitation group will receive
12 individualised, 1 h, vestibular rehabilitation sessions over
a 12week period, typically on a weekly basis. Sessions will
be supervised by the Treating Therapist. Each participant
will practice a selection from the following type of
exercises:
 Eye, head, and postural exercises that provoke a
patient’s symptoms
 Gaze stabilization exercises
 Exercises to re-train postural alignment and
movement strategies
 Re-training sensory strategies
 Learning to adapt postural strategies to changing
contexts
 Dual task training while walking
 Postural orientation exercises
 Neuromuscular (ankle-hip-stepping motor
strategies) postural strategies.
The exercises will be determined following an initial
clinical assessment of oculomotor function, balance and
mobility based on subjective report and objective tests of
the VOR and eye-head coordination, the mini balance
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evaluation system test (mini-BEST test) [62], motion
sensitivity quotient test [63], the gait assessment and
intervention tool (G.A.I.T) [64] and a visual assessment
of postural alignment. The Treating Therapist will select
exercises in partnership with the participant during the
supervised session. Progress in specific areas will be ob-
jectively assessed at each supervised session, any con-
cerns will be discussed, exercises that have not yet been
included in the home programme added and practised,
and existing exercises modified to gradually increase task
difficulty. Each participant will be provided with an indi-
vidualised home exercise programme of 3–5 exercises to
practise each for 1-min, twice daily on days they do not
have a session with the therapist. This will include video
links to a demonstration of the exercise and progression
rules. For those with any reported symptoms of mi-
graine, at first, three exercises only will be provided but
progressed to five exercises if no noticeable exacerbation
of symptoms beyond the exercise period is noted. Exer-
cises will target vestibular-related symptoms; for ex-
ample, if VOR is affected, gaze stabilisation training will
always be included. One out of the five exercises can tar-
get other systems deemed relevant (by the Treating
Therapist or participant) to balance and mobility (e.g.
mobilisation or stretches for reduced neck motion). At
the last supervised session, a home maintenance exercise
programme will be provided.
Adherence and standardisation / fidelity to the
interventions
Both groups of participants will be asked to complete a
daily diary to record the duration of home exercise prac-
tice. This data will be reported as percentage completion
of prescribed exercises. In addition, adherence in the
customised group will be reported as the number of
face-to-face sessions the participant attended.
The Treating Therapists based at the two sites will be
responsible for delivering the interventions. Therapists
will attend a 2 day training course at the start of the trial
which will cover the theory and practice of vestibular re-
habilitation, trial methods and the importance of adher-
ing to protocol. The Treating Therapists will complete a
standardised proforma outlining the exercises taught in
both groups, the agreed frequency of training as well as
advice provided in the one-to-one or telephone follow
ups. This will enable assessment of intervention fidelity
and potential contamination effects.
Data collection and outcome measures
Participant characteristics including demographics, type
of MS, medication and co-morbidities will be docu-
mented at baseline using a customised CRF. Participants
will additionally have a clinical screen for vestibulopathy
[29, 65, 66]. This includes HINTS (the head impulse
sign, presence and type of nystagmus and skew devi-
ation) and truncal ataxia [29, 65, 66]. Potential factors
affecting balance and mobility [67], including objective
measures of isometric knee extensor strength (assessed
in sitting using a strain gauge), distal leg sensation (as
determined by 10 g monofilaments), reaction time (using
an online program https://faculty.washington.edu/chu
dler/java/redgreen.html) and neck passive range of mo-
tion (using goniometry), will also be assessed.
Standardised and validated clinician-rated assessments
and patient self-reported clinical outcomes will be mea-
sured at baseline prior to randomisation (T0). Baseline
measurements and randomisation (T0) occurs 2 weeks
prior to the participant commencing an intervention.
Measures will also be taken post-intervention at 14
weeks (+/− 2 weeks) post-randomisation (T14) and 26
weeks (+/− 2 weeks) post-randomisation (T26).
Primary outcome measure
The primary outcome measure is the impact of dizziness
on daily function assessed using the DHI at the primary
endpoint of 26 weeks (+/− 2 weeks) post-randomisation,
and will also be collected at the secondary endpoint of
14 weeks (+/− 2 weeks) post-randomisation [58]. The
DHI is a validated 25-item self-report questionnaire that
assesses three domains: functional, emotional and physical.
Responses to each question are graded 0 (no), 2 (some-
times) or 4 (yes). The scores per section are summed to
give a maximum score of 100 points. Higher scores indicate
a greater perceived impact of dizziness. The DHI is reliable
in people with MS (intraclass correlation coefficient = 0.90,
95% confidence limits 0.77–0.96) [68].
The primary economic endpoint is the quality-adjusted
life-year (QALY) assessed using the EQ-5D-5L [69]. QALY
weights will be derived using the ‘cross-walk’ [70] to the
EQ-5D-3L UK tariff [71], as recommended by the National
Institute for Health and Care Excellence (NICE) [72].
Secondary outcome measures
The following outcomes are assessed at both T14 and
T26:
 Functional ambulation using the Dynamic Gait
Index [68, 73–75]
 Static and dynamic visual acuity assessed using an
Early Treatment Diabetic Retinopathy Study (EDTR
S) chart with and without passive head motion (400
yaw rotation at 1.5 Hz) [76, 77]
 Visual dependency assessed using the Rod and Disc
test [78, 79]
 Cognitive impairment and processing speed assessed
using the Symbol Digit Modalities Test (SDMT) [80]
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 Impact of MS on walking assessed using the 12 item
self-report walking scale (MSWS-12) Version 2.0 [81]
 Perceived confidence in performing activities of daily
living assessed using the self-report Activities-
Specific Balance Confidence Scale [82]
 Self-reported symptoms of poor balance and
increased anxiety and arousal assessed using the
Vertigo Symptom Scale- Short Form [59, 83]
 Symptoms of visually induced dizziness symptoms
assessed using the self-report Situational Characteristic
Questionnaire [52]
 Fatigue as assessed using the self-report Fatigue Scale
for Motor and Cognitive functions (FSMC) [84]
 Symptoms of depression and anxiety assessed using
the self-report Hospital Anxiety and Depression
Scale (HADS) [85]
 Health-related quality of life using the 29-item
Multiple Sclerosis Impact Scale (MSIS-29) Version
2.0 [86], a disease specific patient-reported outcome
measure [87]
 QALYs assessed by the Multiple Sclerosis Impact
Scale – eight dimensions (MSIS-8D) and the
Multiple Sclerosis Impact Scale – Eight Dimensions
Patient version (MSIS-8D-P) [88, 89]. Both measures
are based on responses to the MSIS-29, and will be
used in sensitivity analyses
 Retrospective diary of falls over the past month for
baseline measure and prospective daily falls diary
over 12 weeks for assessment 2 (T14) and follow up
(T26)
 Treatment adherence as determined by the use of
patient reported diaries and reported as the
percentage of completed prescribed exercises and
attendance at face to face sessions
 User experience of the intervention will be explored
through brief semi-structured face to face individual
exit interviews based on an interview schedule.
Safety monitoring
Participants will be monitored for adverse events via
completion of adverse events forms, during telephone or
face-to-face contacts as part of the intervention phase
and during follow-up assessments. New or worsening
problems which participants perceive to be related to
participation in VR, as well as any relapses and falls, will
be reported. If a member of the research team becomes
aware of a severe adverse event, they will report this to
the Chief Investigator within 24 h, and the trial sponsor
will be informed. The Trial Management Group and the
Trial Steering Committee will be informed of the details
of all adverse events. There are no special compensation
arrangements for harm arising from the study although
neglectful harm will be covered by the insurance scheme
of the sponsor organisation.
Statistical analysis
A detailed statistical analysis plan (SAP) will be devel-
oped during the delivery phase of the trial, agreed with
an independent statistician, and made publicly available
via the VeRMiS website, prior to final database lock.
The primary analysis of the primary outcome will be
undertaken in line with a modified Intention-to-Treat
(ITT) principle amongst participants with complete data
at baseline and 26 weeks. The primary analysis will util-
ise analysis of covariance (ANCOVA), with robust stand-
ard errors if necessary, comparing DHI at 26 weeks
between the two allocated groups, adjusted for baseline
DHI scores, as well as the minimisation factors described
previously. Between-group mean differences will be pre-
sented with 95% confidence intervals wherever possible,
and hypothesis testing will be undertaken at the 5% sig-
nificance level.
Sensitivity analyses of the primary outcome will be
undertaken, possibly including but not limited to per
protocol or complier-average causal effect (CACE) ana-
lyses. A CACE analysis can provide an unbiased estimate
of the intervention effect based on those who complied
with their allocated group’s protocol. Additional adjust-
ments in the ANCOVA model will be considered, if any
notable imbalances between groups at baseline are
observed, in order to investigate the robustness of the
conclusions of the primary analyses.
Secondary outcomes will also be analysed using
ANCOVA and exploring variable transformations where
appropriate.
Exploratory and subgroup analyses
Exploratory analyses will be considered which will help
to inform future studies. These include:
(a) Exploration of the impact of the following
covariates on changes with treatment:
 diagnosis (central versus peripheral versus
combined vestibulopathy)
 visual dependency as determined by the rod and
disc test
 psychological state as determined by the HADS
 associated symptoms (knee extensor strength,
reaction time, leg sensation, neck range of
motion)
(b) Estimating the diagnostic accuracy of the bedside
tests for vestibulopathy
The sensitivity and specificity of diagnosing central
and peripheral vestibular disorders using the bedside
tests for vestibulopathy compared to laboratory-based
measures will be calculated and presented with 95% con-
fidence intervals for the estimates. This is an exploratory
analysis that will inform future studies. The relationship
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between the diagnosis according to clinical tests and
recovery with rehabilitation will be explored using an
additional subgroup analysis.
Economic evaluation
The economic evaluation will establish the resources
required to provide the customised and booklet based
VR, estimate the cost of the interventions, and conduct a
full cost-effectiveness analysis (CEA). The intervention
costing and CEA, based on within-trial data collection,
will be undertaken from the primary perspective of
NHS/Social Care. Participant and broader societal per-
spectives will be considered in sensitivity analyses. The
CEA will synthesise cost and outcome data to present
incremental cost-effectiveness ratios (ICERs) i.e. the in-
cremental cost per unit of additional outcome. The CEA
will present an ICER for the primary outcome (Dizziness
Handicap Inventory) and the primary economic end-
point of policy relevance (the QALY). Cost-effectiveness
acceptability curves will be presented, as appropriate.
Intervention resource requirements (e.g. physiotherap-
ist time, travel, telephone calls, documentation etc.) and
costs will be estimated by case report forms. Self-
reported health and social care resource use data will be
collected at baseline, 14 weeks (+/− 2 weeks) and 26
weeks (+/− 2 weeks) [90]. This will include primary, sec-
ondary and social care, and participant and carer-related
resource use data. The EQ-5D-5L will be used to esti-
mate QALYs for use as the primary economic endpoint.
Incremental costs and incremental QALYs over 3
months will be used to estimate the cost-per-QALY for
customised VR versus the generic booklet-based exercise.
A sensitivity analysis will also explore the cost-effectiveness
of the intervention when the MSIS-8D or MSIS-8D-P is
used as a condition-specific QALY alternative to the EQ-
5D. Descriptive statistics will summarise the costs (by type
of service) and QALYs. A regression model will be used to
adjust for systematic differences between intervention and
control arms that have not been accounted for by random-
isation. If appropriate, multiple imputation will be used to
correct for bias that may result from data that is missing at
random, e.g. EQ-5D-5L or cost data [91]. Analyses will also
explore uncertainty, and provide a clear, policy-relevant
presentation of findings.
Nested observational study
Treatment plan: Following the diagnosis of BPPV at the ini-
tial screening assessment an Epley or Semont manoeuvre
will be performed for people identified as having a posterior
canal BPPV [57]. The type of manoeuvre chosen will be
recorded and determined by factors such as the ability of
the participant to move and range of motion and pain in
the neck. Participants diagnosed with horizontal canal
BPPV will have treatment with the “barbecue rotation”
manoeuvre [92] or Forced Prolonged Position [93]. After
the manoeuvre BPPV will be re-tested. Up to two manoeu-
vres will be performed.
Participants will be asked to return to the clinic after
1 week to re-test for any residual BPPV (session 2. The
appropriate test for BPPV will be repeated. If the test for
BPPV is negative (the primary outcome measure) and
participants are symptom free (based on a Vertigo
Symptom Scale score < 0.3/4) they will be re-tested on
the secondary outcome measures (questionnaires and
Dynamic Gait Index DGI). If the test for BPPV is posi-
tive the appropriate manoeuvre will be repeated (Eply/
Semont or barbecue rotation). After the manoeuvre
BPPV will be re-tested. Up to two manoeuvres will be
performed.
Participants who still have a positive diagnosis of
BPPV in session 2 will be asked to return again to clinic
1 week later. People will be tested for BPPV (the primary
outcome measure) and the secondary outcome measures
(questionnaires and DGI). If the test for BPPV is negative
(the primary outcome measure) and participants are
symptom free (based on a Vertigo Symptom Scale score <
0.3/4) no further action will be taken. If the test for BPPV
is positive or if people have ongoing vertigo and/or bal-
ance and gait impairment they will be provided with a
self-management “Balance rehabilitation” booklet provid-
ing comprehensive advice on VR exercises. The number
of treatment sessions and manoeuvres performed will be
recorded.
Data measurement
Primary and secondary outcomes will be tested at the
end of the treatment session (session 2 or 3) and at 26
and 52 weeks (+/− 2 weeks) after their last treatment
appointment.
The primary outcome measure is the clinical test for
BPPV (Dix- Hallpike) and (horizontal head rotation with
the head in 20o flexion).
Secondary outcome measures will be subjective vestibu-
lar specific questionnaires (Dizziness Handicap Inventory
[68], MS-12 item self-report walking scale Version 2.0
[81]; Activities-Specific Balance Confidence Scale [82];
Vertigo Symptom Scale- Short Form [59, 83]; Situational
Characteristic Questionnaire [52]; Fatigue Scale for Motor
and Cognitive functions (FSMC) [84]; Hospital Anxiety
and Depression Scale (HADS) [85]; 29-item Multiple
Sclerosis Impact Scale [MSIS-29] Version 2.0 [86, 87]) and
the Dynamic Gait Index [68, 94].
Participants will be asked to record re-occurrence of
their symptoms on a re-occurrence/ AE form during this
time if they experience vertigo again so the time of re-
occurrence can be noted. If symptoms reoccur partici-
pants will be referred to their GP.
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Analysis
The analyses for observational study will take cognisance
of the STROBE guidance [95]. The primary interest in
the observational study is on the BPPV reoccurrence
rate. The success rate following treatment for BPPV will
be estimated and presented with 95% confidence intervals.
The short term (1 week) and longer term (6 and 12
months) reoccurrence rates in people with MS will be
estimated and presented with 95% confidence intervals.
These rates will be compared to standardised effect sizes
from previous literature monitoring BPPV treatment
outcomes in people with BPPV and without any add-
itional pathology.
Data management, audit and monitoring
Data will be recorded on study specific CRFs by the re-
search therapists. Study data will be managed using RED-
Cap electronic data capture tools hosted by PenCTU.
Double data entry will be undertaken and discrepancies
will be clarified using the original paper CRFs.
Participants’ anonymity will be maintained on all re-
search documents. Data will be collected and stored at
the University of Plymouth for a minimum of 10 years in
accordance with the Data Protection Act 1988 and
GDPR regulations 2018 and will be accessible for the
purposes of monitoring, auditing, or at the request of
the regulatory agency.
Trial management and oversight committees
Two committees are involved in trial setup, management
and oversight: The Trial Management Group (TMG)
and the Trial Steering Committee (TSC). The TMG
consists of members of the research team with represen-
tation from the CTU and the trial Sponsor. The TMG
meets approximately monthly and oversees the general
management of the trial and release of the trial results
and publications. The TSC consists of members who are
mainly independent of the sponsors and investigators
(chair, external statistician and lay member). The TSC
meets approximately every 6 months and will monitor
reports of adverse events, recruitment and attrition rates,
the project timeline and finances. It has the ability to see
unblinded adverse event data if it is perceived that the
frequency of events is higher than anticipated and advise
on trial progression.
Dissemination plan
On completion of the trial, the full study report will be
accessible on the study website page (https://www.
plymouth.ac.uk/research/vermis), as will the trial proto-
col and statistical analysis plan. The protocol has been
written and published in line with SPIRIT guidelines
[96]. Publications will follow CONSORT guidance [97],
including the extension for Patient Reported Outcomes
(CONSORT PRO) [98], and the template for intervention
description and replication (TiDIER) guidelines [99]. Con-
solidated Health Economic Evaluation Reporting Standards
(CHEERS) guidelines for reporting cost-effectiveness
studies will be followed [100]. Authorship of the intended
articles will be the study team; professional writers will not
be used. Dissemination will target users, clinicians and
researchers. Results will be presented at national and
international conferences and through MS organisa-
tion newsletters and talks to local and national sup-
port groups. If the customised VR programme is
shown to be superior to generic VR rehabilitation,
the training materials (treatment manual, training
videos on assessment and treatment) will be made
available via the study website. We would also aim,
in close collaboration with the UK MS Society, to
implement training programmes to teach healthcare
professionals who regularly see people with MS on
the techniques required for diagnosis and treatment.
All participants, with their consent, will receive
notifications of trial progress and outcomes through
study-specific newsletters.
Discussion
Preliminary evidence suggests that people with MS may
benefit from vestibular rehabilitation [38, 39]. However,
in previous trials the exact cause of any dizziness has
not been defined. This is important as recent work sug-
gests that a substantial proportion of people with MS
have BPPV which requires management through differ-
ent techniques to VR [22, 23]. The overall design of the
current study allows people with a discrete diagnosis of
peripheral or central vestibulopathy to be identified for
the RCT whilst providing appropriate treatment for
other causes of vertigo and/or dizziness (i.e. BPPV).
Within the United Kingdom, people with MS are not
routinely seen by neuro-otologists despite the relatively
high incidence of vestibular-symptoms; therefore, this
study design overcomes potential ethical issues over not
providing timely treatment for BPPV identified through
screening for the RCT.
The study employs comprehensive screening involving
clinical and laboratory testing of vestibular function to
define the cause of the symptoms. In people with MS
with defined vestibulopathy, the prognosis for treatment
with VR may depend on the person’s presentation such
as the cause of any central vestibulopathy and the pres-
ence of additional sensorimotor, cognitive and affective
impairments. These could affect the recovery process,
vestibular compensation, and the ability to undertake VR
[27, 101]. Type of vestibulopathy (central or peripheral) and
severity of presentation (defined according to the DHI) are
therefore minimisation factors in the randomisation process.
Fampridine (Dalframpridine, 4-aminopyridine) blocks K+
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channels that become exposed during the demyelination
process. It improves walking in ~ 39% of people with MS.
[102] It is also used in the treatment of episodic ataxia
[103] with some preliminary evidence suggesting it may
improve symptoms of ataxia in people with hereditary
cerebellar ataxia [104]. In people with MS, fampridine
has been shown in case reports to additionally improve
internuclear opthalmoplegia [105] and upper limb
ataxia [106] although side effects of dizziness have been
reported [107–109]. Therefore, as fampridine may have
an effect on the central vestibular pathways and their
connections to / from the cerebellum in people with
MS, it is also included as a factor in the minimszation
algorithm.
This study uses laboratory-based measures to aid with
the diagnosis of the cause of vestibulopathy. However,
access to these tests may not be readily available within
the wider healthcare system to diagnose people with MS.
As described above, understanding the exact cause of
vestibulopathy may impact on prognosis and therefore
management strategies. Therefore, bedside tests for
vestibulopathy will also be taken and their sensitivity
and specificity and ability to predict recovery with the
rehabilitation interventions explored. This will provide
preliminary explorative data as to applicability of such
tests instead of laboratory-based measures to clinically
screen and to aid implementation of findings in the
wider healthcare setting.
Exclusion criteria include the use of vestibular seda-
tives because their use is discouraged in clinical practice
for chronic vestibular conditions as it is felt to interfere
with the vestibular compensation process [28]. Some
anti-emetics, such as prochlorperazine, can also decrease
migraine but following chronic (> 1 month) use of this
medication there can be a rebound migraine when it is
stopped [110]. Therefore, people who have been taking
vestibular sedatives for more than 1month will be ex-
cluded. However, if with approval of their neurologist
and/or GP, they stop the medication then they will be
eligible to take part in the trial after a 6 week wash out
period.
Migraine can involve the vestibular system resulting
in prodromal symptoms such as vertigo [111]. Although
there are preliminary trials suggesting that vestibular
migraine can be managed with VR there are other
interventions such as lifestyle strategies, reduction in
triggers and pharmacotherapy that need to be consid-
ered [112, 113]. This, and the differences in presenta-
tion and potential prognosis, mean that people with
severe migraine (with or without overt vestibular signs)
are excluded from the trial. The number of people ex-
cluded for this reason will be monitored and reported
on the CONSORT diagram. People with less severe
migraine will be included in the trial if they have signs
of vestibulopathy. Based on clinical experience, a lower
number of exercises will be initially provided (three
compared to five exercises) to avoid potential migraine
exacerbation.
Trial status
Recruitment started in January 2019 and is ongoing.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12883-020-01983-y.
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